ENTA - Enanta Pharmaceuticals, Inc.
| Previous Close | 86.28 |
| Open | 85.93 |
| Bid | 82.55 x 200 |
| Ask | 90.00 x 100 |
| Day's Range | 85.93 - 88.66 |
| 52 Week Range | 29.46 - 95.91 |
| Volume | 93,424 |
| Avg. Volume | 219,088 |
| Market Cap | 1.676B |
| Beta | 1.49 |
| PE Ratio (TTM) | 49.97 |
| EPS (TTM) | 1.75 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 91.75 |
- ACCESSWIRE•5 days ago
Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH
Stock Monitor: CASI Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Enanta Pharma, Inc. (NASDAQ: ENTA ) ("Enanta"). ...
- Business Wire•9 days ago
Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress™ 2018
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s wholly-owned development programs, including EP-027367, one of Enanta’s novel core inhibitors in preclinical testing targeting hepatitis B virus , and EDP-305, an FXR agonist in development ...
- Zacks•12 days ago
FDA Okays Label Expansion of Pacira's Exparel's, Stock Up
Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.
- Zacks•15 days ago
Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
Let us look at the factors that have led to the increase in share price of Emergent (EBS).
Market Realist•15 days agoA Look at Enanta Pharmaceuticals’ Financial Performance
In 1Q18, Enanta Pharmaceuticals (ENTA) generated total revenues of $38.1 million compared with $10.4 million in 1Q17. The company derives revenues from royalties and milestone payments under its collaboration agreement with AbbVie (ABBV).
Market Realist•15 days agoExploring Enanta Pharmaceuticals’ Product Pipeline
Enanta Pharmaceuticals (ENTA) is working on multiple compounds that selectively bind to and activate the farnesoid X receptor (or FXR). As the company’s lead FXR agonist, EDP-305 is designed to take advantage of increased binding interactions with the receptor.
- Market Realist•15 days ago
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.
- Zacks•15 days ago
Novo Nordisk Obtains Licence for Sickle Cell Disease Program
Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
- Zacks•16 days ago
Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session
Shares of Rigel Pharmaceuticals (RIGL) rose over 8% yesterday.
- Zacks•17 days ago
Bio-Path Leukemia Combo Study Shows Positive Early Data
Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.
- GlobeNewswire•17 days ago
Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018
NEW YORK, April 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•18 days ago
Alkermes Sinks as FDA Refuses Depression Drug Review
Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).
- Zacks•19 days ago
Edge Therapeutics Loses Edge on Failure of Late-Stage Study
Edge Therapeutics (EDGE) plummeted significantly after the company announced discontinuation of the pivotal late stage study on lead candidate.
- Business Wire•24 days ago
Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s wholly-owned development programs, including EP-027367, one of Enanta’s novel core inhibitors in preclinical testing for hepatitis B virus , and EDP-305, an FXR agonist in development for non-alcoholic ...
- Zacks•last month
Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?
Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.
- Zacks•last month
Novo Nordisk Poised on Strong Pipeline Amid Competition
Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.
- Zacks•last month
Alexion (ALXN) Gains On Positive Date From Lead Candidate
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
- Zacks•last month
ArQule (ARQL) in Focus: Stock Moves 15.6% Higher
Shares of ArQule (ARQL) rose nearly 16% yesterday.
- Zacks•last month
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress
Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.
- Zacks•last month
Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
- Zacks•last month
Aradigm Files MAA for Bronchiectasis Candidate in the EU
Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.
- Zacks•last month
Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump
It seems to be a wise decision for investors to drop Portola Pharmaceuticals (PTLA) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
- Zacks•last month
Pfizer Gets FDA Panel Backing for New Indication for Xeljanz
Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .
- Zacks•last month
Corcept Plans Korlym Label Expansion, Pipeline in Progress
Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.
- Zacks•last month
Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.
